1、Life Sciences PracticeHow AI can accelerate R&D for cell and gene therapiesCell and gene therapies show significant promise but need substantial innovation to unlock full potential for patients.Scaling digital and analytics in discovery and R&D is part of the solution.November 2022 KTSDESIGN/SCIENCE

2、 PHOTO LIBRARY/Getty ImagesThis article is a collaborative effort by Mayank Bhandari,Amelia Chang,Thomas Devenyns,Alex Devereson,Alberto Loche,and Lieven Van der Veken,representing views from McKinseys Life Sciences Practice.Novel modalities carry huge potential.1 Within oncology,for example,cell th

3、erapy is expected to become the third-largest segment across all modalities(behind antibodies and small molecules)by 2030,with 35 percent CAGR in sales over 202130(Exhibit 1).Gene-and RNA-based therapies,on the other hand,are unlikely to play a major role in the short to medium term,although there a

4、re currently more than one hundred such assets in Phase IIII studies.Bringing novel cell and gene therapy(CGT)modalities to patients successfully remains challenging.Notable headwinds include the complexity and heterogeneity of the solution space,manufacturing and supply chain challenges(especially

5、for personalized therapies),and the difficulty of appropriately matching therapies to the suitable patient endotypes.Moreover,while AI applications are taking off in the wider biopharmaceutical R&D context,companies are only starting to explore how to apply their potential to CGT.There is significan

6、t untapped opportunity in the industry to scale AI within the CGT value chain.Biotechnology companies enabled by machine learning(ML)that focus on novel modalities are still rare.Moderna is perhaps the most mature example,with a strongly articulated ten-year vision to have digital and analytics at i